BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27458154)

  • 41. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).
    Liu HJ; Lam HC; Baglini CV; Nijmeh J; Cottrill AA; Chan SY; Henske EP
    Oncogene; 2019 Dec; 38(49):7367-7383. PubMed ID: 31420607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis.
    Yu J; Astrinidis A; Henske EP
    Am J Respir Crit Care Med; 2001 Oct; 164(8 Pt 1):1537-40. PubMed ID: 11704609
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
    Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
    Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.
    Priolo C; Ricoult SJ; Khabibullin D; Filippakis H; Yu J; Manning BD; Clish C; Henske EP
    Am J Respir Cell Mol Biol; 2015 Jul; 53(1):33-41. PubMed ID: 25780943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.
    Himes BE; Obraztsova K; Lian L; Shumyatcher M; Rue R; Atochina-Vasserman EN; Hur SK; Bartolomei MS; Evans JF; Krymskaya VP
    PLoS One; 2018; 13(5):e0197105. PubMed ID: 29758070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
    Krymskaya VP
    Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
    Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
    Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.
    Fujita A; Ando K; Kobayashi E; Mitani K; Okudera K; Nakashima M; Miyatake S; Tsurusaki Y; Saitsu H; Seyama K; Miyake N; Matsumoto N
    Hum Genet; 2016 Jan; 135(1):61-8. PubMed ID: 26563443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene.
    Pacheco-Rodriguez G; Kumaki F; Steagall WK; Zhang Y; Ikeda Y; Lin JP; Billings EM; Moss J
    J Immunol; 2009 Feb; 182(3):1270-7. PubMed ID: 19155472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
    Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
    PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
    Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
    Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis.
    Li C; Li N; Liu X; Zhang EY; Sun Y; Masuda K; Li J; Sun J; Morrison T; Li X; Chen Y; Wang J; Karim NA; Zhang Y; Blenis J; Reginato MJ; Henske EP; Yu JJ
    JCI Insight; 2016 Nov; 1(19):e86629. PubMed ID: 27882343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.
    Li C; Lee PS; Sun Y; Gu X; Zhang E; Guo Y; Wu CL; Auricchio N; Priolo C; Li J; Csibi A; Parkhitko A; Morrison T; Planaguma A; Kazani S; Israel E; Xu KF; Henske EP; Blenis J; Levy BD; Kwiatkowski D; Yu JJ
    J Exp Med; 2014 Jan; 211(1):15-28. PubMed ID: 24395886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting SPHK1/S1PR3-regulated S-1-P metabolic disorder triggers autophagic cell death in pulmonary lymphangiomyomatosis (LAM).
    Li F; Zhang Y; Lin Z; Yan L; Liu Q; Li Y; Pei X; Feng Y; Han X; Yang J; Zheng F; Li T; Zhang Y; Fu Z; Shao D; Yu J; Li C
    Cell Death Dis; 2022 Dec; 13(12):1065. PubMed ID: 36543771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death.
    Shrestha S; Adib E; Imani J; Aguiar DJ; Lamattina AM; Tassew DD; Henske EP; Perrella MA; Priolo C; El-Chemaly S
    J Biol Chem; 2022 Nov; 298(11):102580. PubMed ID: 36220392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chromatin remodeling by rosuvastatin normalizes TSC2-/meth cell phenotype through the expression of tuberin.
    Lesma E; Ancona S; Orpianesi E; Grande V; Di Giulio AM; Gorio A
    J Pharmacol Exp Ther; 2013 May; 345(2):180-8. PubMed ID: 23426956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
    Liu HJ; Krymskaya VP; Henske EP
    Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.
    Ikeda Y; Taveira-DaSilva AM; Pacheco-Rodriguez G; Steagall WK; El-Chemaly S; Gochuico BR; May RM; Hathaway OM; Li S; Wang JA; Darling TN; Stylianou M; Moss J
    Am J Physiol Lung Cell Mol Physiol; 2011 Jan; 300(1):L64-72. PubMed ID: 21036916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.
    Ruiz de Garibay G; Herranz C; Llorente A; Boni J; Serra-Musach J; Mateo F; Aguilar H; Gómez-Baldó L; Petit A; Vidal A; Climent F; Hernández-Losa J; Cordero Á; González-Suárez E; Sánchez-Mut JV; Esteller M; Llatjós R; Varela M; López JI; García N; Extremera AI; Gumà A; Ortega R; Plà MJ; Fernández A; Pernas S; Falo C; Morilla I; Campos M; Gil M; Román A; Molina-Molina M; Ussetti P; Laporta R; Valenzuela C; Ancochea J; Xaubet A; Casanova Á; Pujana MA
    PLoS One; 2015; 10(7):e0132546. PubMed ID: 26167915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.